Detalhe da pesquisa
1.
TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer.
Future Oncol
; 20(9): 493-505, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37882449
2.
Real-World Treatment Patterns Among Patients With Metastatic Castration-Resistant Prostate Cancer: Results From an International Study.
Oncologist
; 28(9): e737-e747, 2023 09 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37014097
3.
Real-World Treatment Trends Among Patients with Metastatic Castration-Sensitive Prostate Cancer: Results from an International Study.
Oncologist
; 28(9): 780-789, 2023 09 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37014080
4.
Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer.
Oncologist
; 28(5): 414-424, 2023 05 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36952230
5.
Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study.
Oncologist
; 28(10): 845-855, 2023 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37318349
6.
Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer from the United States, Europe, and Israel.
BMC Cancer
; 22(1): 1343, 2022 Dec 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36550413
7.
Real-world multi-country study of BRCA1/2 mutation testing among adult women with HER2-negative advanced breast cancer.
Future Oncol
; 18(9): 1089-1101, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35098723
8.
Clinical characteristics, treatment patterns, and outcomes in adult patients with germline BRCA1/2-mutated, HER2-negative advanced breast cancer: a retrospective medical record review in the United States.
Front Oncol
; 14: 1341665, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38817906
9.
Treatment Patterns and Clinical Outcomes Among Patients With Metastatic Prostate Cancer Harboring Homologous Recombination Repair Mutations.
Clin Genitourin Cancer
; 22(3): 102080, 2024 Mar 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38653037
10.
Real-World Study of Regional Differences in Patient Demographics, Clinical Characteristics, and BRCA1/2 Mutation Testing in Patients with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in the United States, Europe, and Israel.
Adv Ther
; 40(1): 331-348, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36333567
11.
The impact of race on survival in metastatic prostate cancer: a systematic literature review.
Prostate Cancer Prostatic Dis
; 26(3): 461-474, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37592001
12.
Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1.
Eur Urol
; 83(4): 352-360, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35750582
13.
Treatment Patterns, Safety, and Patient Reported Outcomes among Adult Women with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer with or without, or with Unknown, BRCA1/2 Mutation(s): Results of a Real-World Study from the United States, United Kingdom, and four EU Countries.
Breast Care (Basel)
; 17(5): 460-469, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36684399
14.
Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2âNegative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel.
Breast
; 66: 236-244, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36368161
15.
BRCA1/2 Mutation Testing in Patients with HER2-Negative Advanced Breast Cancer: Real-World Data from the United States, Europe, and Israel.
Cancers (Basel)
; 14(21)2022 Nov 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36358816
16.
Payer perceptions on the use of patient-reported outcomes in oncology decision making.
J Manag Care Spec Pharm
; 28(2): 188-195, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34806908
17.
Awareness and Availability of Routine Germline BRCA1/2 Mutation Testing in Patients with Advanced Breast Cancer in Germany.
Breast Care (Basel)
; 17(1): 40-46, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35350106
18.
Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015-2020.
Clin Cancer Res
; 28(1): 27-35, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34667027
19.
Payer perceptions on the use of economic models in oncology decision making.
J Manag Care Spec Pharm
; 27(11): 1560-1567, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34714111
20.
Payer perceptions of the use of real-world evidence in oncology-based decision making.
J Manag Care Spec Pharm
; 27(8): 1096-1105, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34337998